The first participants in an early stage clinical trial have received a dose of the mRNA flu shot, and Moderna plans to enroll about 180 people.
Moderna said mRNA technology could provide advantages over current flu shot technology, which is only about 40 percent to 60 percent effective and takes six to nine months to prepare.
An mRNA flu shot could also be combined with other vaccines, including a COVID-19 vaccine, so one shot could provide protection from multiple viruses.
“Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses,” Moderna CEO Stéphane Bancel said in a news release.
Read the full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
